255 related articles for article (PubMed ID: 20407744)
1. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
Bowker SL; Yasui Y; Veugelers P; Johnson JA
Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744
[TBL] [Abstract][Full Text] [Related]
2. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
3. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Johnson JA; Majumdar SR; Simpson SH; Toth EL
Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
5. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
Eurich DT; Simpson SH; Majumdar SR; Johnson JA
Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899
[TBL] [Abstract][Full Text] [Related]
6. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
[TBL] [Abstract][Full Text] [Related]
7. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
8. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
9. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
10. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetes Care; 2012 Jan; 35(1):119-24. PubMed ID: 22100960
[TBL] [Abstract][Full Text] [Related]
11. Predictors of insulin initiation in metformin and sulfonylurea users in primary care practices: the role of kidney function.
Kostev K; Dippel FW; Rathmann W
J Diabetes Sci Technol; 2014 Sep; 8(5):1023-8. PubMed ID: 24876433
[TBL] [Abstract][Full Text] [Related]
12. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
13. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
14. Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetologia; 2015 Jan; 58(1):50-8. PubMed ID: 25205223
[TBL] [Abstract][Full Text] [Related]
15. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
16. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.
Wheeler S; Moore K; Forsberg CW; Riley K; Floyd JS; Smith NL; Boyko EJ
Diabetologia; 2013 Sep; 56(9):1934-43. PubMed ID: 23797633
[TBL] [Abstract][Full Text] [Related]
17. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ; Poole CD; Gale EA
Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
[TBL] [Abstract][Full Text] [Related]
18. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.
Corrao G; Romio SA; Zambon A; Merlino L; Bosi E; Scavini M
Eur J Clin Pharmacol; 2011 Mar; 67(3):289-99. PubMed ID: 21088829
[TBL] [Abstract][Full Text] [Related]
19. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Hamid Z; Simmons DL
Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
[No Abstract] [Full Text] [Related]
20. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
